Home » Stocks » ALLO

Allogene Therapeutics, Inc. (ALLO)

Stock Price: $22.55 USD -0.02 (-0.09%)
Updated Jul 29, 2021 12:36 PM EDT - Market open
Market Cap 3.17B
Revenue (ttm) 38.35M
Net Income (ttm) -228.76M
Shares Out 141.54M
EPS (ttm) -1.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $22.55
Previous Close $22.57
Change ($) -0.02
Change (%) -0.09%
Day's Open 22.56
Day's Range 22.16 - 22.97
Day's Volume 209,436
52-Week Range 21.10 - 44.92

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET

2 days ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...

2 weeks ago - GlobeNewsWire

Allogene's (ALLO) next-generation allogeneic CAR T therapy, ALLO-605, gets Fast Track designation from the FDA to treat patients with relapsed or refractory multiple myeloma.

4 weeks ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...

4 weeks ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. & BOSTON & SHANGHAI--(BUSINESS WIRE)--Allogene Overland Biopharm today announced the appointment of Shuyuan Yao, Ph.D. as Chief Executive Officer.

1 month ago - Business Wire

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

The stock price of Allogene Therapeutics has seen a 13% drop over the last five trading days. The decline is surprising given the company's announcement of positive results from early clinical trials fo...

2 months ago - Forbes

SOUTH SAN FRANCISCO, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T...

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T...

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T...

2 months ago - GlobeNewsWire

Allogene (ALLO) beats earnings and revenue estimates in the first quarter. Stock gains 1.7%.

2 months ago - Zacks Investment Research

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 47.92% and 56.54%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

CD19 Program Highlights

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and PARIS, April 28, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR ...

3 months ago - GlobeNewsWire

Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET

3 months ago - GlobeNewsWire

FDA grants RMAT designation to Allogene's (ALLO) CAR T cell product candidate for multiple myeloma, ALLO-715. The designation will help accelerate development and review of the candidate.

3 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...

3 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...

3 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and STAMFORD, Conn., April 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allog...

3 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...

3 months ago - GlobeNewsWire

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?

4 months ago - Zacks Investment Research

Allogene (ALLO) reports no revenues for the fourth quarter of 2020.

5 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...

5 months ago - GlobeNewsWire

Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET

5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...

5 months ago - GlobeNewsWire

Allogene Therapeutics (NASDAQ: ALLO) shares are trading higher Tuesday after Stifel upgraded the stock from Hold to Buy and raised its price target from $33 to $43 per share. Allogene is a U.S.-based cl...

Other stocks mentioned: NVS, SEEL, SELB
6 months ago - Benzinga

SOUTH SAN FRANCISCO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...

6 months ago - GlobeNewsWire

The FDA permits Allogene (ALLO) to initiate an early-stage study on its AlloCAR T therapy candidate, ALLO-715, in combination with SpringWorks' nirogacestat in multiple myeloma patients.

7 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...

7 months ago - GlobeNewsWire

Overland Pharmaceuticals will form a $117 million China JV with Allogene Therapeutics to bring allogenic CAR-T drugs to China. Harbour BioMed has out-licensed its fully human SARS-CoV-2 neutralizing ant...

Other stocks mentioned: ABBV, ADCT, BNTX, LEGN, YMAB
7 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif. and BOSTON and SHANGHAI, China, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the developmen...

7 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...

7 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Dec. 06, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...

7 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...

7 months ago - GlobeNewsWire

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?

7 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...

7 months ago - GlobeNewsWire

Allogeneic cell therapies have a significant cost, convenience and efficiency advantage over autologous. Data from three of the leaders: Allogene, Atara and CRISPR are expected in the next 12-to-24 mont...

Other stocks mentioned: ATRA, BMY, CLLS, CRSP, GILD, NVS, PFE
7 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...

8 months ago - GlobeNewsWire

Allogene Therapeutics' (ALLO) CEO David Chang on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Allogene (ALLO) reports no revenues for the third quarter of 2020.

8 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...

8 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...

8 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...

9 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...

9 months ago - GlobeNewsWire

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?

10 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC...

10 months ago - GlobeNewsWire

It's not uncommon for stocks that have significantly outperformed for several months to take a breather.

Other stocks mentioned: DKNG, MYOK, PLUG, UTHR, XLRN, YY
11 months ago - Kiplinger

Allogene (ALLO) reports no revenues for the second quarter of 2020.

11 months ago - Zacks Investment Research

Allogene Therapeutics' (ALLO) CEO David Chang on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...

11 months ago - GlobeNewsWire

About ALLO

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin ... [Read more...]

Industry
Biotechnology
IPO Date
Oct 11, 2018
Stock Exchange
NASDAQ
Ticker Symbol
ALLO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 17 analysts, the average rating for ALLO stock is "Buy." The 12-month stock price forecast is 50.14, which is an increase of 122.35% from the latest price.

Price Target
$50.14
(122.35% upside)
Analyst Consensus: Buy